#METABOLOMICS WORKBENCH ssah9_20230310_161743 DATATRACK_ID:3785 STUDY_ID:ST002521 ANALYSIS_ID:AN004153 PROJECT_ID:PR001623 VERSION 1 CREATED_ON March 16, 2023, 3:14 pm #PROJECT PR:PROJECT_TITLE Wide-Coverage Serum Metabolomic Profiling Reveals a Comprehensive Lipidome PR:PROJECT_TITLE Signature of Ovarian Cancer. PR:PROJECT_SUMMARY Distinguishing ovarian cancer (OC) from other benign or cancerous gynecological PR:PROJECT_SUMMARY malignancies remains a critical unmet medical need with significant implications PR:PROJECT_SUMMARY on patient survival. Substantially better results are observed when women with PR:PROJECT_SUMMARY OC are correctly diagnosed and ensured the right treatment. However, PR:PROJECT_SUMMARY non-specific symptoms along with our lack of understanding of OC pathogenesis PR:PROJECT_SUMMARY hinder its diagnosis, consequently leading to a very low survival rate. PR:PROJECT_SUMMARY Accumulating evidence suggests the link between OC and deregulated lipid PR:PROJECT_SUMMARY metabolism. Most studies, however, are limited by small sample sizes and PR:PROJECT_SUMMARY metabolite coverage, thereby constraining the robustness of the results. Here, PR:PROJECT_SUMMARY we performed a comprehensive serum lipidome profiling of OC and various other PR:PROJECT_SUMMARY gynecological malignancies (non-OC). A relatively large patient cohort with 208 PR:PROJECT_SUMMARY OC and 137 non-OC patients, including 93 OC patients with early-stage OC, was PR:PROJECT_SUMMARY recruited from two independent clinical sites in South Korea. Samples were PR:PROJECT_SUMMARY analyzed with high-coverage liquid chromatography high-resolution mass PR:PROJECT_SUMMARY spectrometry, providing extensive lipidome coverage with 994 successfully PR:PROJECT_SUMMARY annotated lipid features. Lipidome differences between OC and other PR:PROJECT_SUMMARY gynecological malignancies were investigated via statistical and machine PR:PROJECT_SUMMARY learning approaches. Our data suggest that lipidome alterations unique to OC can PR:PROJECT_SUMMARY be detected as early as when the cancer is localized, and those changes amplify PR:PROJECT_SUMMARY as the diseases progresses. Comparison of the relative lipid abundances revealed PR:PROJECT_SUMMARY specific patterns based on lipid class with most lipid classes showing decreased PR:PROJECT_SUMMARY abundance in ovarian cancer. This study provides a systemic analysis of lipidome PR:PROJECT_SUMMARY alterations in OC, emphasizing the potential of circulating lipids as a PR:PROJECT_SUMMARY complementary class of blood-based biomarkers for OC diagnosis. PR:INSTITUTE Georgia Institute of Technology PR:LAST_NAME Sah PR:FIRST_NAME Samyukta PR:ADDRESS 901 Atlantic Dr NW, Atlanta, GA 30318 PR:EMAIL ssah9@gatech.edu PR:PHONE 574-678-0124 #STUDY ST:STUDY_TITLE Wide-Coverage Serum Metabolomic Profiling Reveals a Comprehensive Lipidome ST:STUDY_TITLE Signature of Ovarian Cancer. ST:STUDY_SUMMARY Distinguishing ovarian cancer (OC) from other benign or cancerous gynecological ST:STUDY_SUMMARY malignancies remains a critical unmet medical need with significant implications ST:STUDY_SUMMARY on patient survival. Substantially better results are observed when women with ST:STUDY_SUMMARY OC are correctly diagnosed and ensured the right treatment. However, ST:STUDY_SUMMARY non-specific symptoms along with our lack of understanding of OC pathogenesis ST:STUDY_SUMMARY hinder its diagnosis, consequently leading to a very low survival rate. ST:STUDY_SUMMARY Accumulating evidence suggests the link between OC and deregulated lipid ST:STUDY_SUMMARY metabolism. Most studies, however, are limited by small sample sizes and ST:STUDY_SUMMARY metabolite coverage, thereby constraining the robustness of the results. Here, ST:STUDY_SUMMARY we performed a comprehensive serum lipidome profiling of OC and various other ST:STUDY_SUMMARY gynecological malignancies (non-OC). A relatively large patient cohort with 208 ST:STUDY_SUMMARY OC and 137 non-OC patients, including 93 OC patients with early-stage OC, was ST:STUDY_SUMMARY recruited from two independent clinical sites in South Korea. Samples were ST:STUDY_SUMMARY analyzed with high-coverage liquid chromatography high-resolution mass ST:STUDY_SUMMARY spectrometry, providing extensive lipidome coverage with 994 successfully ST:STUDY_SUMMARY annotated lipid features. Lipidome differences between OC and other ST:STUDY_SUMMARY gynecological malignancies were investigated via statistical and machine ST:STUDY_SUMMARY learning approaches. Our data suggest that lipidome alterations unique to OC can ST:STUDY_SUMMARY be detected as early as when the cancer is localized, and those changes amplify ST:STUDY_SUMMARY as the diseases progresses. Comparison of the relative lipid abundances revealed ST:STUDY_SUMMARY specific patterns based on lipid class with most lipid classes showing decreased ST:STUDY_SUMMARY abundance in ovarian cancer. This study provides a systemic analysis of lipidome ST:STUDY_SUMMARY alterations in OC, emphasizing the potential of circulating lipids as a ST:STUDY_SUMMARY complementary class of blood-based biomarkers for OC diagnosis. ST:INSTITUTE Georgia Institute of Technology ST:LAST_NAME Sah ST:FIRST_NAME Samyukta ST:ADDRESS 901 Atlantic Dr NW, Atlanta, GA 30318 ST:EMAIL ssah9@gatech.edu ST:PHONE 574-678-0124 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS - BOT1 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT1 SUBJECT_SAMPLE_FACTORS - BOT2 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT2 SUBJECT_SAMPLE_FACTORS - BOT3 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT3 SUBJECT_SAMPLE_FACTORS - BOT4 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT4 SUBJECT_SAMPLE_FACTORS - BOT5 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT5 SUBJECT_SAMPLE_FACTORS - BOT6 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT6 SUBJECT_SAMPLE_FACTORS - BOT7 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT7 SUBJECT_SAMPLE_FACTORS - BOT8 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT8 SUBJECT_SAMPLE_FACTORS - BOT9 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT9 SUBJECT_SAMPLE_FACTORS - BOT10 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT10 SUBJECT_SAMPLE_FACTORS - BOT11 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT11 SUBJECT_SAMPLE_FACTORS - BOT12 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT12 SUBJECT_SAMPLE_FACTORS - BOT13 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT13 SUBJECT_SAMPLE_FACTORS - BOT14 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT14 SUBJECT_SAMPLE_FACTORS - BOT15 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT15 SUBJECT_SAMPLE_FACTORS - BOT16 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT16 SUBJECT_SAMPLE_FACTORS - BOT17 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT17 SUBJECT_SAMPLE_FACTORS - BOT18 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT18 SUBJECT_SAMPLE_FACTORS - BOT19 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT19 SUBJECT_SAMPLE_FACTORS - BOT20 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT20 SUBJECT_SAMPLE_FACTORS - BOT21 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT21 SUBJECT_SAMPLE_FACTORS - BOT22 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT22 SUBJECT_SAMPLE_FACTORS - BOT23 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT23 SUBJECT_SAMPLE_FACTORS - BOT24 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT24 SUBJECT_SAMPLE_FACTORS - BOT25 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT25 SUBJECT_SAMPLE_FACTORS - BOT26 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT26 SUBJECT_SAMPLE_FACTORS - BOT27 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT27 SUBJECT_SAMPLE_FACTORS - BOT28 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT28 SUBJECT_SAMPLE_FACTORS - BOT29 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT29 SUBJECT_SAMPLE_FACTORS - BOT30 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT30 SUBJECT_SAMPLE_FACTORS - BOT31 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT31 SUBJECT_SAMPLE_FACTORS - BOT32 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT32 SUBJECT_SAMPLE_FACTORS - BOT33 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT33 SUBJECT_SAMPLE_FACTORS - BOT34 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT34 SUBJECT_SAMPLE_FACTORS - BOT35 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT35 SUBJECT_SAMPLE_FACTORS - BOT36 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT36 SUBJECT_SAMPLE_FACTORS - BOT37 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT37 SUBJECT_SAMPLE_FACTORS - BOT38 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT38 SUBJECT_SAMPLE_FACTORS - BOT39 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT39 SUBJECT_SAMPLE_FACTORS - BOT40 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT40 SUBJECT_SAMPLE_FACTORS - BOT41 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT41 SUBJECT_SAMPLE_FACTORS - BOT42 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT42 SUBJECT_SAMPLE_FACTORS - BOT43 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT43 SUBJECT_SAMPLE_FACTORS - BOT44 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT44 SUBJECT_SAMPLE_FACTORS - BOT45 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT45 SUBJECT_SAMPLE_FACTORS - BOT46 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT46 SUBJECT_SAMPLE_FACTORS - BOT47 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT47 SUBJECT_SAMPLE_FACTORS - BOT48 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT48 SUBJECT_SAMPLE_FACTORS - BOT49 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT49 SUBJECT_SAMPLE_FACTORS - BOT50 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT50 SUBJECT_SAMPLE_FACTORS - BOT51 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT51 SUBJECT_SAMPLE_FACTORS - BOT52 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT52 SUBJECT_SAMPLE_FACTORS - BOT53 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT53 SUBJECT_SAMPLE_FACTORS - BOT54 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT54 SUBJECT_SAMPLE_FACTORS - BOT55 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT55 SUBJECT_SAMPLE_FACTORS - BOT56 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT56 SUBJECT_SAMPLE_FACTORS - BOT57 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT57 SUBJECT_SAMPLE_FACTORS - BOT58 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT58 SUBJECT_SAMPLE_FACTORS - BOT59 Treatment:Benign Ovarian Tumor RAW_FILE_NAME=BOT59 SUBJECT_SAMPLE_FACTORS - BUT1 Treatment:benign uterine tumor RAW_FILE_NAME=BUT1 SUBJECT_SAMPLE_FACTORS - BUT2 Treatment:benign uterine tumor RAW_FILE_NAME=BUT2 SUBJECT_SAMPLE_FACTORS - BUT3 Treatment:benign uterine tumor RAW_FILE_NAME=BUT3 SUBJECT_SAMPLE_FACTORS - BUT4 Treatment:benign uterine tumor RAW_FILE_NAME=BUT4 SUBJECT_SAMPLE_FACTORS - BUT5 Treatment:benign uterine tumor RAW_FILE_NAME=BUT5 SUBJECT_SAMPLE_FACTORS - BUT6 Treatment:benign uterine tumor RAW_FILE_NAME=BUT6 SUBJECT_SAMPLE_FACTORS - BUT7 Treatment:benign uterine tumor RAW_FILE_NAME=BUT7 SUBJECT_SAMPLE_FACTORS - BUT8 Treatment:benign uterine tumor RAW_FILE_NAME=BUT8 SUBJECT_SAMPLE_FACTORS - BUT9 Treatment:benign uterine tumor RAW_FILE_NAME=BUT9 SUBJECT_SAMPLE_FACTORS - BUT10 Treatment:benign uterine tumor RAW_FILE_NAME=BUT10 SUBJECT_SAMPLE_FACTORS - BUT11 Treatment:benign uterine tumor RAW_FILE_NAME=BUT11 SUBJECT_SAMPLE_FACTORS - BUT12 Treatment:benign uterine tumor RAW_FILE_NAME=BUT12 SUBJECT_SAMPLE_FACTORS - BUT13 Treatment:benign uterine tumor RAW_FILE_NAME=BUT13 SUBJECT_SAMPLE_FACTORS - BUT14 Treatment:benign uterine tumor RAW_FILE_NAME=BUT14 SUBJECT_SAMPLE_FACTORS - BUT15 Treatment:benign uterine tumor RAW_FILE_NAME=BUT15 SUBJECT_SAMPLE_FACTORS - BUT16 Treatment:benign uterine tumor RAW_FILE_NAME=BUT16 SUBJECT_SAMPLE_FACTORS - BUT17 Treatment:benign uterine tumor RAW_FILE_NAME=BUT17 SUBJECT_SAMPLE_FACTORS - BUT18 Treatment:benign uterine tumor RAW_FILE_NAME=BUT18 SUBJECT_SAMPLE_FACTORS - BUT19 Treatment:benign uterine tumor RAW_FILE_NAME=BUT19 SUBJECT_SAMPLE_FACTORS - BUT20 Treatment:benign uterine tumor RAW_FILE_NAME=BUT20 SUBJECT_SAMPLE_FACTORS - BUT21 Treatment:benign uterine tumor RAW_FILE_NAME=BUT21 SUBJECT_SAMPLE_FACTORS - BUT22 Treatment:benign uterine tumor RAW_FILE_NAME=BUT22 SUBJECT_SAMPLE_FACTORS - BUT23 Treatment:benign uterine tumor RAW_FILE_NAME=BUT23 SUBJECT_SAMPLE_FACTORS - BUT24 Treatment:benign uterine tumor RAW_FILE_NAME=BUT24 SUBJECT_SAMPLE_FACTORS - BUT25 Treatment:benign uterine tumor RAW_FILE_NAME=BUT25 SUBJECT_SAMPLE_FACTORS - BUT26 Treatment:benign uterine tumor RAW_FILE_NAME=BUT26 SUBJECT_SAMPLE_FACTORS - BUT27 Treatment:benign uterine tumor RAW_FILE_NAME=BUT27 SUBJECT_SAMPLE_FACTORS - BUT28 Treatment:benign uterine tumor RAW_FILE_NAME=BUT28 SUBJECT_SAMPLE_FACTORS - BUT29 Treatment:benign uterine tumor RAW_FILE_NAME=BUT29 SUBJECT_SAMPLE_FACTORS - BUT30 Treatment:benign uterine tumor RAW_FILE_NAME=BUT30 SUBJECT_SAMPLE_FACTORS - BUT31 Treatment:benign uterine tumor RAW_FILE_NAME=BUT31 SUBJECT_SAMPLE_FACTORS - CC1 Treatment:Cervical cancer RAW_FILE_NAME=CC1 SUBJECT_SAMPLE_FACTORS - CC2 Treatment:Cervical cancer RAW_FILE_NAME=CC2 SUBJECT_SAMPLE_FACTORS - CC3 Treatment:Cervical cancer RAW_FILE_NAME=CC3 SUBJECT_SAMPLE_FACTORS - CC4 Treatment:Cervical cancer RAW_FILE_NAME=CC4 SUBJECT_SAMPLE_FACTORS - CC5 Treatment:Cervical cancer RAW_FILE_NAME=CC5 SUBJECT_SAMPLE_FACTORS - CC6 Treatment:Cervical cancer RAW_FILE_NAME=CC6 SUBJECT_SAMPLE_FACTORS - CC7 Treatment:Cervical cancer RAW_FILE_NAME=CC7 SUBJECT_SAMPLE_FACTORS - CC8 Treatment:Cervical cancer RAW_FILE_NAME=CC8 SUBJECT_SAMPLE_FACTORS - CC9 Treatment:Cervical cancer RAW_FILE_NAME=CC9 SUBJECT_SAMPLE_FACTORS - CC10 Treatment:Cervical cancer RAW_FILE_NAME=CC10 SUBJECT_SAMPLE_FACTORS - CC11 Treatment:Cervical cancer RAW_FILE_NAME=CC11 SUBJECT_SAMPLE_FACTORS - CC12 Treatment:Cervical cancer RAW_FILE_NAME=CC12 SUBJECT_SAMPLE_FACTORS - CC13 Treatment:Cervical cancer RAW_FILE_NAME=CC13 SUBJECT_SAMPLE_FACTORS - CC14 Treatment:Cervical cancer RAW_FILE_NAME=CC14 SUBJECT_SAMPLE_FACTORS - CC15 Treatment:Cervical cancer RAW_FILE_NAME=CC15 SUBJECT_SAMPLE_FACTORS - CC16 Treatment:Cervical cancer RAW_FILE_NAME=CC16 SUBJECT_SAMPLE_FACTORS - CC17 Treatment:Cervical cancer RAW_FILE_NAME=CC17 SUBJECT_SAMPLE_FACTORS - CC18 Treatment:Cervical cancer RAW_FILE_NAME=CC18 SUBJECT_SAMPLE_FACTORS - CC19 Treatment:Cervical cancer RAW_FILE_NAME=CC19 SUBJECT_SAMPLE_FACTORS - CC20 Treatment:Cervical cancer RAW_FILE_NAME=CC20 SUBJECT_SAMPLE_FACTORS - CC21 Treatment:Cervical cancer RAW_FILE_NAME=CC21 SUBJECT_SAMPLE_FACTORS - CC22 Treatment:Cervical cancer RAW_FILE_NAME=CC22 SUBJECT_SAMPLE_FACTORS - CC23 Treatment:Cervical cancer RAW_FILE_NAME=CC23 SUBJECT_SAMPLE_FACTORS - CC24 Treatment:Cervical cancer RAW_FILE_NAME=CC24 SUBJECT_SAMPLE_FACTORS - CC25 Treatment:Cervical cancer RAW_FILE_NAME=CC25 SUBJECT_SAMPLE_FACTORS - CC26 Treatment:Cervical cancer RAW_FILE_NAME=CC26 SUBJECT_SAMPLE_FACTORS - CC27 Treatment:Cervical cancer RAW_FILE_NAME=CC27 SUBJECT_SAMPLE_FACTORS - CC28 Treatment:Cervical cancer RAW_FILE_NAME=CC28 SUBJECT_SAMPLE_FACTORS - CC29 Treatment:Cervical cancer RAW_FILE_NAME=CC29 SUBJECT_SAMPLE_FACTORS - CC30 Treatment:Cervical cancer RAW_FILE_NAME=CC30 SUBJECT_SAMPLE_FACTORS - CC31 Treatment:Cervical cancer RAW_FILE_NAME=CC31 SUBJECT_SAMPLE_FACTORS - CC32 Treatment:Cervical cancer RAW_FILE_NAME=CC32 SUBJECT_SAMPLE_FACTORS - CC33 Treatment:Cervical cancer RAW_FILE_NAME=CC33 SUBJECT_SAMPLE_FACTORS - CC34 Treatment:Cervical cancer RAW_FILE_NAME=CC34 SUBJECT_SAMPLE_FACTORS - CC35 Treatment:Cervical cancer RAW_FILE_NAME=CC35 SUBJECT_SAMPLE_FACTORS - CC36 Treatment:Cervical cancer RAW_FILE_NAME=CC36 SUBJECT_SAMPLE_FACTORS - CC37 Treatment:Cervical cancer RAW_FILE_NAME=CC37 SUBJECT_SAMPLE_FACTORS - CC38 Treatment:Cervical cancer RAW_FILE_NAME=CC38 SUBJECT_SAMPLE_FACTORS - CC39 Treatment:Cervical cancer RAW_FILE_NAME=CC39 SUBJECT_SAMPLE_FACTORS - CC40 Treatment:Cervical cancer RAW_FILE_NAME=CC40 SUBJECT_SAMPLE_FACTORS - CC41 Treatment:Cervical cancer RAW_FILE_NAME=CC41 SUBJECT_SAMPLE_FACTORS - CC42 Treatment:Cervical cancer RAW_FILE_NAME=CC42 SUBJECT_SAMPLE_FACTORS - CC43 Treatment:Cervical cancer RAW_FILE_NAME=CC43 SUBJECT_SAMPLE_FACTORS - CC44 Treatment:Cervical cancer RAW_FILE_NAME=CC44 SUBJECT_SAMPLE_FACTORS - CC45 Treatment:Cervical cancer RAW_FILE_NAME=CC45 SUBJECT_SAMPLE_FACTORS - CC46 Treatment:Cervical cancer RAW_FILE_NAME=CC46 SUBJECT_SAMPLE_FACTORS - CC47 Treatment:Cervical cancer RAW_FILE_NAME=CC47 SUBJECT_SAMPLE_FACTORS - CC48 Treatment:Cervical cancer RAW_FILE_NAME=CC48 SUBJECT_SAMPLE_FACTORS - CC49 Treatment:Cervical cancer RAW_FILE_NAME=CC49 SUBJECT_SAMPLE_FACTORS - CC50 Treatment:Cervical cancer RAW_FILE_NAME=CC50 SUBJECT_SAMPLE_FACTORS - CC51 Treatment:Cervical cancer RAW_FILE_NAME=CC51 SUBJECT_SAMPLE_FACTORS - CC52 Treatment:Cervical cancer RAW_FILE_NAME=CC52 SUBJECT_SAMPLE_FACTORS - CC53 Treatment:Cervical cancer RAW_FILE_NAME=CC53 SUBJECT_SAMPLE_FACTORS - CC54 Treatment:Cervical cancer RAW_FILE_NAME=CC54 SUBJECT_SAMPLE_FACTORS - CC55 Treatment:Cervical cancer RAW_FILE_NAME=CC55 SUBJECT_SAMPLE_FACTORS - CC56 Treatment:Cervical cancer RAW_FILE_NAME=CC56 SUBJECT_SAMPLE_FACTORS - CC57 Treatment:Cervical cancer RAW_FILE_NAME=CC57 SUBJECT_SAMPLE_FACTORS - CC58 Treatment:Cervical cancer RAW_FILE_NAME=CC58 SUBJECT_SAMPLE_FACTORS - CC59 Treatment:Cervical cancer RAW_FILE_NAME=CC59 SUBJECT_SAMPLE_FACTORS - CC60 Treatment:Cervical cancer RAW_FILE_NAME=CC60 SUBJECT_SAMPLE_FACTORS - OC1 Treatment:Ovarian Cancer RAW_FILE_NAME=OC1 SUBJECT_SAMPLE_FACTORS - OC2 Treatment:Ovarian Cancer RAW_FILE_NAME=OC2 SUBJECT_SAMPLE_FACTORS - OC3 Treatment:Ovarian Cancer RAW_FILE_NAME=OC3 SUBJECT_SAMPLE_FACTORS - OC4 Treatment:Ovarian Cancer RAW_FILE_NAME=OC4 SUBJECT_SAMPLE_FACTORS - OC5 Treatment:Ovarian Cancer RAW_FILE_NAME=OC5 SUBJECT_SAMPLE_FACTORS - OC6 Treatment:Ovarian Cancer RAW_FILE_NAME=OC6 SUBJECT_SAMPLE_FACTORS - OC7 Treatment:Ovarian Cancer RAW_FILE_NAME=OC7 SUBJECT_SAMPLE_FACTORS - OC8 Treatment:Ovarian Cancer RAW_FILE_NAME=OC8 SUBJECT_SAMPLE_FACTORS - OC9 Treatment:Ovarian Cancer RAW_FILE_NAME=OC9 SUBJECT_SAMPLE_FACTORS - OC10 Treatment:Ovarian Cancer RAW_FILE_NAME=OC10 SUBJECT_SAMPLE_FACTORS - OC11 Treatment:Ovarian Cancer RAW_FILE_NAME=OC11 SUBJECT_SAMPLE_FACTORS - OC12 Treatment:Ovarian Cancer RAW_FILE_NAME=OC12 SUBJECT_SAMPLE_FACTORS - OC13 Treatment:Ovarian Cancer RAW_FILE_NAME=OC13 SUBJECT_SAMPLE_FACTORS - OC14 Treatment:Ovarian Cancer RAW_FILE_NAME=OC14 SUBJECT_SAMPLE_FACTORS - OC15 Treatment:Ovarian Cancer RAW_FILE_NAME=OC15 SUBJECT_SAMPLE_FACTORS - OC16 Treatment:Ovarian Cancer RAW_FILE_NAME=OC16 SUBJECT_SAMPLE_FACTORS - OC17 Treatment:Ovarian Cancer RAW_FILE_NAME=OC17 SUBJECT_SAMPLE_FACTORS - OC18 Treatment:Ovarian Cancer RAW_FILE_NAME=OC18 SUBJECT_SAMPLE_FACTORS - OC19 Treatment:Ovarian Cancer RAW_FILE_NAME=OC19 SUBJECT_SAMPLE_FACTORS - OC20 Treatment:Ovarian Cancer RAW_FILE_NAME=OC20 SUBJECT_SAMPLE_FACTORS - OC21 Treatment:Ovarian Cancer RAW_FILE_NAME=OC21 SUBJECT_SAMPLE_FACTORS - OC22 Treatment:Ovarian Cancer RAW_FILE_NAME=OC22 SUBJECT_SAMPLE_FACTORS - OC23 Treatment:Ovarian Cancer RAW_FILE_NAME=OC23 SUBJECT_SAMPLE_FACTORS - OC24 Treatment:Ovarian Cancer RAW_FILE_NAME=OC24 SUBJECT_SAMPLE_FACTORS - OC25 Treatment:Ovarian Cancer RAW_FILE_NAME=OC25 SUBJECT_SAMPLE_FACTORS - OC26 Treatment:Ovarian Cancer RAW_FILE_NAME=OC26 SUBJECT_SAMPLE_FACTORS - OC27 Treatment:Ovarian Cancer RAW_FILE_NAME=OC27 SUBJECT_SAMPLE_FACTORS - OC28 Treatment:Ovarian Cancer RAW_FILE_NAME=OC28 SUBJECT_SAMPLE_FACTORS - OC29 Treatment:Ovarian Cancer RAW_FILE_NAME=OC29 SUBJECT_SAMPLE_FACTORS - OC30 Treatment:Ovarian Cancer RAW_FILE_NAME=OC30 SUBJECT_SAMPLE_FACTORS - OC31 Treatment:Ovarian Cancer RAW_FILE_NAME=OC31 SUBJECT_SAMPLE_FACTORS - OC32 Treatment:Ovarian Cancer RAW_FILE_NAME=OC32 SUBJECT_SAMPLE_FACTORS - OC33 Treatment:Ovarian Cancer RAW_FILE_NAME=OC33 SUBJECT_SAMPLE_FACTORS - OC34 Treatment:Ovarian Cancer RAW_FILE_NAME=OC34 SUBJECT_SAMPLE_FACTORS - OC35 Treatment:Ovarian Cancer RAW_FILE_NAME=OC35 SUBJECT_SAMPLE_FACTORS - OC36 Treatment:Ovarian Cancer RAW_FILE_NAME=OC36 SUBJECT_SAMPLE_FACTORS - OC37 Treatment:Ovarian Cancer RAW_FILE_NAME=OC37 SUBJECT_SAMPLE_FACTORS - OC38 Treatment:Ovarian Cancer RAW_FILE_NAME=OC38 SUBJECT_SAMPLE_FACTORS - OC39 Treatment:Ovarian Cancer RAW_FILE_NAME=OC39 SUBJECT_SAMPLE_FACTORS - OC40 Treatment:Ovarian Cancer RAW_FILE_NAME=OC40 SUBJECT_SAMPLE_FACTORS - OC41 Treatment:Ovarian Cancer RAW_FILE_NAME=OC41 SUBJECT_SAMPLE_FACTORS - OC42 Treatment:Ovarian Cancer RAW_FILE_NAME=OC42 SUBJECT_SAMPLE_FACTORS - OC43 Treatment:Ovarian Cancer RAW_FILE_NAME=OC43 SUBJECT_SAMPLE_FACTORS - OC44 Treatment:Ovarian Cancer RAW_FILE_NAME=OC44 SUBJECT_SAMPLE_FACTORS - OC45 Treatment:Ovarian Cancer RAW_FILE_NAME=OC45 SUBJECT_SAMPLE_FACTORS - OC46 Treatment:Ovarian Cancer RAW_FILE_NAME=OC46 SUBJECT_SAMPLE_FACTORS - OC47 Treatment:Ovarian Cancer RAW_FILE_NAME=OC47 SUBJECT_SAMPLE_FACTORS - OC48 Treatment:Ovarian Cancer RAW_FILE_NAME=OC48 SUBJECT_SAMPLE_FACTORS - OC49 Treatment:Ovarian Cancer RAW_FILE_NAME=OC49 SUBJECT_SAMPLE_FACTORS - OC50 Treatment:Ovarian Cancer RAW_FILE_NAME=OC50 SUBJECT_SAMPLE_FACTORS - OC51 Treatment:Ovarian Cancer RAW_FILE_NAME=OC51 SUBJECT_SAMPLE_FACTORS - OC52 Treatment:Ovarian Cancer RAW_FILE_NAME=OC52 SUBJECT_SAMPLE_FACTORS - OC53 Treatment:Ovarian Cancer RAW_FILE_NAME=OC53 SUBJECT_SAMPLE_FACTORS - OC54 Treatment:Ovarian Cancer RAW_FILE_NAME=OC54 SUBJECT_SAMPLE_FACTORS - OC55 Treatment:Ovarian Cancer RAW_FILE_NAME=OC55 SUBJECT_SAMPLE_FACTORS - OC56 Treatment:Ovarian Cancer RAW_FILE_NAME=OC56 SUBJECT_SAMPLE_FACTORS - OC57 Treatment:Ovarian Cancer RAW_FILE_NAME=OC57 SUBJECT_SAMPLE_FACTORS - OC58 Treatment:Ovarian Cancer RAW_FILE_NAME=OC58 SUBJECT_SAMPLE_FACTORS - OC59 Treatment:Ovarian Cancer RAW_FILE_NAME=OC59 SUBJECT_SAMPLE_FACTORS - OC60 Treatment:Ovarian Cancer RAW_FILE_NAME=OC60 SUBJECT_SAMPLE_FACTORS - OC61 Treatment:Ovarian Cancer RAW_FILE_NAME=OC61 SUBJECT_SAMPLE_FACTORS - OC62 Treatment:Ovarian Cancer RAW_FILE_NAME=OC62 SUBJECT_SAMPLE_FACTORS - OC63 Treatment:Ovarian Cancer RAW_FILE_NAME=OC63 SUBJECT_SAMPLE_FACTORS - OC64 Treatment:Ovarian Cancer RAW_FILE_NAME=OC64 SUBJECT_SAMPLE_FACTORS - OC65 Treatment:Ovarian Cancer RAW_FILE_NAME=OC65 SUBJECT_SAMPLE_FACTORS - OC66 Treatment:Ovarian Cancer RAW_FILE_NAME=OC66 SUBJECT_SAMPLE_FACTORS - OC67 Treatment:Ovarian Cancer RAW_FILE_NAME=OC67 SUBJECT_SAMPLE_FACTORS - OC68 Treatment:Ovarian Cancer RAW_FILE_NAME=OC68 SUBJECT_SAMPLE_FACTORS - OC69 Treatment:Ovarian Cancer RAW_FILE_NAME=OC69 SUBJECT_SAMPLE_FACTORS - OC70 Treatment:Ovarian Cancer RAW_FILE_NAME=OC70 SUBJECT_SAMPLE_FACTORS - OC71 Treatment:Ovarian Cancer RAW_FILE_NAME=OC71 SUBJECT_SAMPLE_FACTORS - OC72 Treatment:Ovarian Cancer RAW_FILE_NAME=OC72 SUBJECT_SAMPLE_FACTORS - OC73 Treatment:Ovarian Cancer RAW_FILE_NAME=OC73 SUBJECT_SAMPLE_FACTORS - OC74 Treatment:Ovarian Cancer RAW_FILE_NAME=OC74 SUBJECT_SAMPLE_FACTORS - OC75 Treatment:Ovarian Cancer RAW_FILE_NAME=OC75 SUBJECT_SAMPLE_FACTORS - OC76 Treatment:Ovarian Cancer RAW_FILE_NAME=OC76 SUBJECT_SAMPLE_FACTORS - OC77 Treatment:Ovarian Cancer RAW_FILE_NAME=OC77 SUBJECT_SAMPLE_FACTORS - OC78 Treatment:Ovarian Cancer RAW_FILE_NAME=OC78 SUBJECT_SAMPLE_FACTORS - OC79 Treatment:Ovarian Cancer RAW_FILE_NAME=OC79 SUBJECT_SAMPLE_FACTORS - OC80 Treatment:Ovarian Cancer RAW_FILE_NAME=OC80 SUBJECT_SAMPLE_FACTORS - OC81 Treatment:Ovarian Cancer RAW_FILE_NAME=OC81 SUBJECT_SAMPLE_FACTORS - OC82 Treatment:Ovarian Cancer RAW_FILE_NAME=OC82 SUBJECT_SAMPLE_FACTORS - OC83 Treatment:Ovarian Cancer RAW_FILE_NAME=OC83 SUBJECT_SAMPLE_FACTORS - OC84 Treatment:Ovarian Cancer RAW_FILE_NAME=OC84 SUBJECT_SAMPLE_FACTORS - OC85 Treatment:Ovarian Cancer RAW_FILE_NAME=OC85 SUBJECT_SAMPLE_FACTORS - OC86 Treatment:Ovarian Cancer RAW_FILE_NAME=OC86 SUBJECT_SAMPLE_FACTORS - OC87 Treatment:Ovarian Cancer RAW_FILE_NAME=OC87 SUBJECT_SAMPLE_FACTORS - OC88 Treatment:Ovarian Cancer RAW_FILE_NAME=OC88 SUBJECT_SAMPLE_FACTORS - OC89 Treatment:Ovarian Cancer RAW_FILE_NAME=OC89 SUBJECT_SAMPLE_FACTORS - OC90 Treatment:Ovarian Cancer RAW_FILE_NAME=OC90 SUBJECT_SAMPLE_FACTORS - OC91 Treatment:Ovarian Cancer RAW_FILE_NAME=OC91 SUBJECT_SAMPLE_FACTORS - OC92 Treatment:Ovarian Cancer RAW_FILE_NAME=OC92 SUBJECT_SAMPLE_FACTORS - OC93 Treatment:Ovarian Cancer RAW_FILE_NAME=OC93 SUBJECT_SAMPLE_FACTORS - OC94 Treatment:Ovarian Cancer RAW_FILE_NAME=OC94 SUBJECT_SAMPLE_FACTORS - OC95 Treatment:Ovarian Cancer RAW_FILE_NAME=OC95 SUBJECT_SAMPLE_FACTORS - OC96 Treatment:Ovarian Cancer RAW_FILE_NAME=OC96 SUBJECT_SAMPLE_FACTORS - OC97 Treatment:Ovarian Cancer RAW_FILE_NAME=OC97 SUBJECT_SAMPLE_FACTORS - OC98 Treatment:Ovarian Cancer RAW_FILE_NAME=OC98 SUBJECT_SAMPLE_FACTORS - OC99 Treatment:Ovarian Cancer RAW_FILE_NAME=OC99 SUBJECT_SAMPLE_FACTORS - OC100 Treatment:Ovarian Cancer RAW_FILE_NAME=OC100 SUBJECT_SAMPLE_FACTORS - OC101 Treatment:Ovarian Cancer RAW_FILE_NAME=OC101 SUBJECT_SAMPLE_FACTORS - OC102 Treatment:Ovarian Cancer RAW_FILE_NAME=OC102 SUBJECT_SAMPLE_FACTORS - OC103 Treatment:Ovarian Cancer RAW_FILE_NAME=OC103 SUBJECT_SAMPLE_FACTORS - OC104 Treatment:Ovarian Cancer RAW_FILE_NAME=OC104 SUBJECT_SAMPLE_FACTORS - OC105 Treatment:Ovarian Cancer RAW_FILE_NAME=OC105 SUBJECT_SAMPLE_FACTORS - OC106 Treatment:Ovarian Cancer RAW_FILE_NAME=OC106 SUBJECT_SAMPLE_FACTORS - OC107 Treatment:Ovarian Cancer RAW_FILE_NAME=OC107 SUBJECT_SAMPLE_FACTORS - OC108 Treatment:Ovarian Cancer RAW_FILE_NAME=OC108 SUBJECT_SAMPLE_FACTORS - OC109 Treatment:Ovarian Cancer RAW_FILE_NAME=OC109 SUBJECT_SAMPLE_FACTORS - OC110 Treatment:Ovarian Cancer RAW_FILE_NAME=OC110 SUBJECT_SAMPLE_FACTORS - OC111 Treatment:Ovarian Cancer RAW_FILE_NAME=OC111 SUBJECT_SAMPLE_FACTORS - OC112 Treatment:Ovarian Cancer RAW_FILE_NAME=OC112 SUBJECT_SAMPLE_FACTORS - OC113 Treatment:Ovarian Cancer RAW_FILE_NAME=OC113 SUBJECT_SAMPLE_FACTORS - OC114 Treatment:Ovarian Cancer RAW_FILE_NAME=OC114 SUBJECT_SAMPLE_FACTORS - OC115 Treatment:Ovarian Cancer RAW_FILE_NAME=OC115 SUBJECT_SAMPLE_FACTORS - OC116 Treatment:Ovarian Cancer RAW_FILE_NAME=OC116 SUBJECT_SAMPLE_FACTORS - OC117 Treatment:Ovarian Cancer RAW_FILE_NAME=OC117 SUBJECT_SAMPLE_FACTORS - OC118 Treatment:Ovarian Cancer RAW_FILE_NAME=OC118 SUBJECT_SAMPLE_FACTORS - OC119 Treatment:Ovarian Cancer RAW_FILE_NAME=OC119 SUBJECT_SAMPLE_FACTORS - OC120 Treatment:Ovarian Cancer RAW_FILE_NAME=OC120 SUBJECT_SAMPLE_FACTORS - OC121 Treatment:Ovarian Cancer RAW_FILE_NAME=OC121 SUBJECT_SAMPLE_FACTORS - OC122 Treatment:Ovarian Cancer RAW_FILE_NAME=OC122 SUBJECT_SAMPLE_FACTORS - OC123 Treatment:Ovarian Cancer RAW_FILE_NAME=OC123 SUBJECT_SAMPLE_FACTORS - OC124 Treatment:Ovarian Cancer RAW_FILE_NAME=OC124 SUBJECT_SAMPLE_FACTORS - OC125 Treatment:Ovarian Cancer RAW_FILE_NAME=OC125 SUBJECT_SAMPLE_FACTORS - OC126 Treatment:Ovarian Cancer RAW_FILE_NAME=OC126 SUBJECT_SAMPLE_FACTORS - OC127 Treatment:Ovarian Cancer RAW_FILE_NAME=OC127 SUBJECT_SAMPLE_FACTORS - OC128 Treatment:Ovarian Cancer RAW_FILE_NAME=OC128 SUBJECT_SAMPLE_FACTORS - OC129 Treatment:Ovarian Cancer RAW_FILE_NAME=OC129 SUBJECT_SAMPLE_FACTORS - OC130 Treatment:Ovarian Cancer RAW_FILE_NAME=OC130 SUBJECT_SAMPLE_FACTORS - OC131 Treatment:Ovarian Cancer RAW_FILE_NAME=OC131 SUBJECT_SAMPLE_FACTORS - OC132 Treatment:Ovarian Cancer RAW_FILE_NAME=OC132 SUBJECT_SAMPLE_FACTORS - OC133 Treatment:Ovarian Cancer RAW_FILE_NAME=OC133 SUBJECT_SAMPLE_FACTORS - OC134 Treatment:Ovarian Cancer RAW_FILE_NAME=OC134 SUBJECT_SAMPLE_FACTORS - OC135 Treatment:Ovarian Cancer RAW_FILE_NAME=OC135 SUBJECT_SAMPLE_FACTORS - OC136 Treatment:Ovarian Cancer RAW_FILE_NAME=OC136 SUBJECT_SAMPLE_FACTORS - OC137 Treatment:Ovarian Cancer RAW_FILE_NAME=OC137 SUBJECT_SAMPLE_FACTORS - OC138 Treatment:Ovarian Cancer RAW_FILE_NAME=OC138 SUBJECT_SAMPLE_FACTORS - OC139 Treatment:Ovarian Cancer RAW_FILE_NAME=OC139 SUBJECT_SAMPLE_FACTORS - OC140 Treatment:Ovarian Cancer RAW_FILE_NAME=OC140 SUBJECT_SAMPLE_FACTORS - OC141 Treatment:Ovarian Cancer RAW_FILE_NAME=OC141 SUBJECT_SAMPLE_FACTORS - OC142 Treatment:Ovarian Cancer RAW_FILE_NAME=OC142 SUBJECT_SAMPLE_FACTORS - OC143 Treatment:Ovarian Cancer RAW_FILE_NAME=OC143 SUBJECT_SAMPLE_FACTORS - OC144 Treatment:Ovarian Cancer RAW_FILE_NAME=OC144 SUBJECT_SAMPLE_FACTORS - OC145 Treatment:Ovarian Cancer RAW_FILE_NAME=OC145 SUBJECT_SAMPLE_FACTORS - OC146 Treatment:Ovarian Cancer RAW_FILE_NAME=OC146 SUBJECT_SAMPLE_FACTORS - OC147 Treatment:Ovarian Cancer RAW_FILE_NAME=OC147 SUBJECT_SAMPLE_FACTORS - OC148 Treatment:Ovarian Cancer RAW_FILE_NAME=OC148 SUBJECT_SAMPLE_FACTORS - OC149 Treatment:Ovarian Cancer RAW_FILE_NAME=OC149 SUBJECT_SAMPLE_FACTORS - OC150 Treatment:Ovarian Cancer RAW_FILE_NAME=OC150 SUBJECT_SAMPLE_FACTORS - OC151 Treatment:Ovarian Cancer RAW_FILE_NAME=OC151 SUBJECT_SAMPLE_FACTORS - OC152 Treatment:Ovarian Cancer RAW_FILE_NAME=OC152 SUBJECT_SAMPLE_FACTORS - OC153 Treatment:Ovarian Cancer RAW_FILE_NAME=OC153 SUBJECT_SAMPLE_FACTORS - OC154 Treatment:Ovarian Cancer RAW_FILE_NAME=OC154 SUBJECT_SAMPLE_FACTORS - OC155 Treatment:Ovarian Cancer RAW_FILE_NAME=OC155 SUBJECT_SAMPLE_FACTORS - OC156 Treatment:Ovarian Cancer RAW_FILE_NAME=OC156 SUBJECT_SAMPLE_FACTORS - OC157 Treatment:Ovarian Cancer RAW_FILE_NAME=OC157 SUBJECT_SAMPLE_FACTORS - OC158 Treatment:Ovarian Cancer RAW_FILE_NAME=OC158 SUBJECT_SAMPLE_FACTORS - OC159 Treatment:Ovarian Cancer RAW_FILE_NAME=OC159 SUBJECT_SAMPLE_FACTORS - OC160 Treatment:Ovarian Cancer RAW_FILE_NAME=OC160 SUBJECT_SAMPLE_FACTORS - OC161 Treatment:Ovarian Cancer RAW_FILE_NAME=OC161 SUBJECT_SAMPLE_FACTORS - OC162 Treatment:Ovarian Cancer RAW_FILE_NAME=OC162 SUBJECT_SAMPLE_FACTORS - OC163 Treatment:Ovarian Cancer RAW_FILE_NAME=OC163 SUBJECT_SAMPLE_FACTORS - OC164 Treatment:Ovarian Cancer RAW_FILE_NAME=OC164 SUBJECT_SAMPLE_FACTORS - OC165 Treatment:Ovarian Cancer RAW_FILE_NAME=OC165 SUBJECT_SAMPLE_FACTORS - OC166 Treatment:Ovarian Cancer RAW_FILE_NAME=OC166 SUBJECT_SAMPLE_FACTORS - OC167 Treatment:Ovarian Cancer RAW_FILE_NAME=OC167 SUBJECT_SAMPLE_FACTORS - OC168 Treatment:Ovarian Cancer RAW_FILE_NAME=OC168 SUBJECT_SAMPLE_FACTORS - OC169 Treatment:Ovarian Cancer RAW_FILE_NAME=OC169 SUBJECT_SAMPLE_FACTORS - OC170 Treatment:Ovarian Cancer RAW_FILE_NAME=OC170 SUBJECT_SAMPLE_FACTORS - OC171 Treatment:Ovarian Cancer RAW_FILE_NAME=OC171 SUBJECT_SAMPLE_FACTORS - OC172 Treatment:Ovarian Cancer RAW_FILE_NAME=OC172 SUBJECT_SAMPLE_FACTORS - OC173 Treatment:Ovarian Cancer RAW_FILE_NAME=OC173 SUBJECT_SAMPLE_FACTORS - OC174 Treatment:Ovarian Cancer RAW_FILE_NAME=OC174 SUBJECT_SAMPLE_FACTORS - OC175 Treatment:Ovarian Cancer RAW_FILE_NAME=OC175 SUBJECT_SAMPLE_FACTORS - OC176 Treatment:Ovarian Cancer RAW_FILE_NAME=OC176 SUBJECT_SAMPLE_FACTORS - OC177 Treatment:Ovarian Cancer RAW_FILE_NAME=OC177 SUBJECT_SAMPLE_FACTORS - OC178 Treatment:Ovarian Cancer RAW_FILE_NAME=OC178 SUBJECT_SAMPLE_FACTORS - OC179 Treatment:Ovarian Cancer RAW_FILE_NAME=OC179 SUBJECT_SAMPLE_FACTORS - OC180 Treatment:Ovarian Cancer RAW_FILE_NAME=OC180 SUBJECT_SAMPLE_FACTORS - OC181 Treatment:Ovarian Cancer RAW_FILE_NAME=OC181 SUBJECT_SAMPLE_FACTORS - OC182 Treatment:Ovarian Cancer RAW_FILE_NAME=OC182 SUBJECT_SAMPLE_FACTORS - OC183 Treatment:Ovarian Cancer RAW_FILE_NAME=OC183 SUBJECT_SAMPLE_FACTORS - OC184 Treatment:Ovarian Cancer RAW_FILE_NAME=OC184 SUBJECT_SAMPLE_FACTORS - OC185 Treatment:Ovarian Cancer RAW_FILE_NAME=OC185 SUBJECT_SAMPLE_FACTORS - OC186 Treatment:Ovarian Cancer RAW_FILE_NAME=OC186 SUBJECT_SAMPLE_FACTORS - OC187 Treatment:Ovarian Cancer RAW_FILE_NAME=OC187 SUBJECT_SAMPLE_FACTORS - OC188 Treatment:Ovarian Cancer RAW_FILE_NAME=OC188 SUBJECT_SAMPLE_FACTORS - OC189 Treatment:Ovarian Cancer RAW_FILE_NAME=OC189 SUBJECT_SAMPLE_FACTORS - OC190 Treatment:Ovarian Cancer RAW_FILE_NAME=OC190 SUBJECT_SAMPLE_FACTORS - OC191 Treatment:Ovarian Cancer RAW_FILE_NAME=OC191 SUBJECT_SAMPLE_FACTORS - OC192 Treatment:Ovarian Cancer RAW_FILE_NAME=OC192 SUBJECT_SAMPLE_FACTORS - OC193 Treatment:Ovarian Cancer RAW_FILE_NAME=OC193 SUBJECT_SAMPLE_FACTORS - OC194 Treatment:Ovarian Cancer RAW_FILE_NAME=OC194 SUBJECT_SAMPLE_FACTORS - OC195 Treatment:Ovarian Cancer RAW_FILE_NAME=OC195 SUBJECT_SAMPLE_FACTORS - OC196 Treatment:Ovarian Cancer RAW_FILE_NAME=OC196 SUBJECT_SAMPLE_FACTORS - OC197 Treatment:Ovarian Cancer RAW_FILE_NAME=OC197 SUBJECT_SAMPLE_FACTORS - OC198 Treatment:Ovarian Cancer RAW_FILE_NAME=OC198 SUBJECT_SAMPLE_FACTORS - OC199 Treatment:Ovarian Cancer RAW_FILE_NAME=OC199 SUBJECT_SAMPLE_FACTORS - OC200 Treatment:Ovarian Cancer RAW_FILE_NAME=OC200 SUBJECT_SAMPLE_FACTORS - OC201 Treatment:Ovarian Cancer RAW_FILE_NAME=OC201 SUBJECT_SAMPLE_FACTORS - OC202 Treatment:Ovarian Cancer RAW_FILE_NAME=OC202 SUBJECT_SAMPLE_FACTORS - OC203 Treatment:Ovarian Cancer RAW_FILE_NAME=OC203 SUBJECT_SAMPLE_FACTORS - OC204 Treatment:Ovarian Cancer RAW_FILE_NAME=OC204 SUBJECT_SAMPLE_FACTORS - OC205 Treatment:Ovarian Cancer RAW_FILE_NAME=OC205 SUBJECT_SAMPLE_FACTORS - OC206 Treatment:Ovarian Cancer RAW_FILE_NAME=OC206 SUBJECT_SAMPLE_FACTORS - OC207 Treatment:Ovarian Cancer RAW_FILE_NAME=OC207 SUBJECT_SAMPLE_FACTORS - OC208 Treatment:Ovarian Cancer RAW_FILE_NAME=OC208 SUBJECT_SAMPLE_FACTORS - OC209 Treatment:Ovarian Cancer RAW_FILE_NAME=OC209 SUBJECT_SAMPLE_FACTORS - OC210 Treatment:Ovarian Cancer RAW_FILE_NAME=OC210 SUBJECT_SAMPLE_FACTORS - OC211 Treatment:Ovarian Cancer RAW_FILE_NAME=OC211 SUBJECT_SAMPLE_FACTORS - OC212 Treatment:Ovarian Cancer RAW_FILE_NAME=OC212 SUBJECT_SAMPLE_FACTORS - OC213 Treatment:Ovarian Cancer RAW_FILE_NAME=OC213 SUBJECT_SAMPLE_FACTORS - OC214 Treatment:Ovarian Cancer RAW_FILE_NAME=OC214 SUBJECT_SAMPLE_FACTORS - OC215 Treatment:Ovarian Cancer RAW_FILE_NAME=OC215 SUBJECT_SAMPLE_FACTORS - OC216 Treatment:Ovarian Cancer RAW_FILE_NAME=OC216 SUBJECT_SAMPLE_FACTORS - OC217 Treatment:Ovarian Cancer RAW_FILE_NAME=OC217 SUBJECT_SAMPLE_FACTORS - OC218 Treatment:Ovarian Cancer RAW_FILE_NAME=OC218 SUBJECT_SAMPLE_FACTORS - OC219 Treatment:Ovarian Cancer RAW_FILE_NAME=OC219 SUBJECT_SAMPLE_FACTORS - OC220 Treatment:Ovarian Cancer RAW_FILE_NAME=OC220 SUBJECT_SAMPLE_FACTORS - OC221 Treatment:Ovarian Cancer RAW_FILE_NAME=OC221 SUBJECT_SAMPLE_FACTORS - OC222 Treatment:Ovarian Cancer RAW_FILE_NAME=OC222 SUBJECT_SAMPLE_FACTORS - OC223 Treatment:Ovarian Cancer RAW_FILE_NAME=OC223 SUBJECT_SAMPLE_FACTORS - OC224 Treatment:Ovarian Cancer RAW_FILE_NAME=OC224 SUBJECT_SAMPLE_FACTORS - OC225 Treatment:Ovarian Cancer RAW_FILE_NAME=OC225 SUBJECT_SAMPLE_FACTORS - OC226 Treatment:Ovarian Cancer RAW_FILE_NAME=OC226 SUBJECT_SAMPLE_FACTORS - OC227 Treatment:Ovarian Cancer RAW_FILE_NAME=OC227 SUBJECT_SAMPLE_FACTORS - OC228 Treatment:Ovarian Cancer RAW_FILE_NAME=OC228 SUBJECT_SAMPLE_FACTORS - OC229 Treatment:Ovarian Cancer RAW_FILE_NAME=OC229 SUBJECT_SAMPLE_FACTORS - OC230 Treatment:Ovarian Cancer RAW_FILE_NAME=OC230 SUBJECT_SAMPLE_FACTORS - OC231 Treatment:Ovarian Cancer RAW_FILE_NAME=OC231 SUBJECT_SAMPLE_FACTORS - OC232 Treatment:Ovarian Cancer RAW_FILE_NAME=OC232 SUBJECT_SAMPLE_FACTORS - OC233 Treatment:Ovarian Cancer RAW_FILE_NAME=OC233 SUBJECT_SAMPLE_FACTORS - OC234 Treatment:Ovarian Cancer RAW_FILE_NAME=OC234 SUBJECT_SAMPLE_FACTORS - OC235 Treatment:Ovarian Cancer RAW_FILE_NAME=OC235 SUBJECT_SAMPLE_FACTORS - OC236 Treatment:Ovarian Cancer RAW_FILE_NAME=OC236 SUBJECT_SAMPLE_FACTORS - OC237 Treatment:Ovarian Cancer RAW_FILE_NAME=OC237 SUBJECT_SAMPLE_FACTORS - OC238 Treatment:Ovarian Cancer RAW_FILE_NAME=OC238 SUBJECT_SAMPLE_FACTORS - OC239 Treatment:Ovarian Cancer RAW_FILE_NAME=OC239 SUBJECT_SAMPLE_FACTORS - OC240 Treatment:Ovarian Cancer RAW_FILE_NAME=OC240 SUBJECT_SAMPLE_FACTORS - OC241 Treatment:Ovarian Cancer RAW_FILE_NAME=OC241 SUBJECT_SAMPLE_FACTORS - OC242 Treatment:Ovarian Cancer RAW_FILE_NAME=OC242 SUBJECT_SAMPLE_FACTORS - OC243 Treatment:Ovarian Cancer RAW_FILE_NAME=OC243 SUBJECT_SAMPLE_FACTORS - OC244 Treatment:Ovarian Cancer RAW_FILE_NAME=OC244 SUBJECT_SAMPLE_FACTORS - OC245 Treatment:Ovarian Cancer RAW_FILE_NAME=OC245 SUBJECT_SAMPLE_FACTORS - OC246 Treatment:Ovarian Cancer RAW_FILE_NAME=OC246 SUBJECT_SAMPLE_FACTORS - OC247 Treatment:Ovarian Cancer RAW_FILE_NAME=OC247 SUBJECT_SAMPLE_FACTORS - OC248 Treatment:Ovarian Cancer RAW_FILE_NAME=OC248 SUBJECT_SAMPLE_FACTORS - OC249 Treatment:Ovarian Cancer RAW_FILE_NAME=OC249 SUBJECT_SAMPLE_FACTORS - OC250 Treatment:Ovarian Cancer RAW_FILE_NAME=OC250 SUBJECT_SAMPLE_FACTORS - OC251 Treatment:Ovarian Cancer RAW_FILE_NAME=OC251 SUBJECT_SAMPLE_FACTORS - OC252 Treatment:Ovarian Cancer RAW_FILE_NAME=OC252 SUBJECT_SAMPLE_FACTORS - OC253 Treatment:Ovarian Cancer RAW_FILE_NAME=OC253 SUBJECT_SAMPLE_FACTORS - OC254 Treatment:Ovarian Cancer RAW_FILE_NAME=OC254 SUBJECT_SAMPLE_FACTORS - OC255 Treatment:Ovarian Cancer RAW_FILE_NAME=OC255 SUBJECT_SAMPLE_FACTORS - OC256 Treatment:Ovarian Cancer RAW_FILE_NAME=OC256 SUBJECT_SAMPLE_FACTORS - OC257 Treatment:Ovarian Cancer RAW_FILE_NAME=OC257 SUBJECT_SAMPLE_FACTORS - OC258 Treatment:Ovarian Cancer RAW_FILE_NAME=OC258 SUBJECT_SAMPLE_FACTORS - OC259 Treatment:Ovarian Cancer RAW_FILE_NAME=OC259 SUBJECT_SAMPLE_FACTORS - OC260 Treatment:Ovarian Cancer RAW_FILE_NAME=OC260 SUBJECT_SAMPLE_FACTORS - OC261 Treatment:Ovarian Cancer RAW_FILE_NAME=OC261 SUBJECT_SAMPLE_FACTORS - OC262 Treatment:Ovarian Cancer RAW_FILE_NAME=OC262 SUBJECT_SAMPLE_FACTORS - OC263 Treatment:Ovarian Cancer RAW_FILE_NAME=OC263 SUBJECT_SAMPLE_FACTORS - OC264 Treatment:Ovarian Cancer RAW_FILE_NAME=OC264 SUBJECT_SAMPLE_FACTORS - OC265 Treatment:Ovarian Cancer RAW_FILE_NAME=OC265 SUBJECT_SAMPLE_FACTORS - OC266 Treatment:Ovarian Cancer RAW_FILE_NAME=OC266 SUBJECT_SAMPLE_FACTORS - OC267 Treatment:Ovarian Cancer RAW_FILE_NAME=OC267 SUBJECT_SAMPLE_FACTORS - OC268 Treatment:Ovarian Cancer RAW_FILE_NAME=OC268 SUBJECT_SAMPLE_FACTORS - OC269 Treatment:Ovarian Cancer RAW_FILE_NAME=OC269 SUBJECT_SAMPLE_FACTORS - OC270 Treatment:Ovarian Cancer RAW_FILE_NAME=OC270 SUBJECT_SAMPLE_FACTORS - OC271 Treatment:Ovarian Cancer RAW_FILE_NAME=OC271 SUBJECT_SAMPLE_FACTORS - OC272 Treatment:Ovarian Cancer RAW_FILE_NAME=OC272 SUBJECT_SAMPLE_FACTORS - OC273 Treatment:Ovarian Cancer RAW_FILE_NAME=OC273 SUBJECT_SAMPLE_FACTORS - B1 Treatment:BRACA positive RAW_FILE_NAME=B1 SUBJECT_SAMPLE_FACTORS - B2 Treatment:BRACA positive RAW_FILE_NAME=B2 SUBJECT_SAMPLE_FACTORS - B3 Treatment:BRACA positive RAW_FILE_NAME=B3 #COLLECTION CO:COLLECTION_SUMMARY Serum samples were collected from two independent tissue banks in South Korea, CO:COLLECTION_SUMMARY Dongsan Hospital Human Tissue Bank and Gangnam Severance Hospital Gene Bank. The CO:COLLECTION_SUMMARY Severance cohort included 185 samples from ovarian cancer patients, 47 from CO:COLLECTION_SUMMARY women with benign ovarian tumor, 50 from invasive cervical cancer and 21 samples CO:COLLECTION_SUMMARY from patients with benign uterine tumor. Blood was collected from all patients CO:COLLECTION_SUMMARY during surgery after anesthesia and at least 8 hours of fasting. In the Dongsan CO:COLLECTION_SUMMARY cohort 88 women had ovarian cancer, 12 had benign ovarian tumor, 10 had benign CO:COLLECTION_SUMMARY uterine tumor, and 9 women had cervical cancer. As with the Severance cohort, CO:COLLECTION_SUMMARY samples from these patients were collected during surgery after anesthesia and CO:COLLECTION_SUMMARY at least 6 hours of fasting. All recruited participants were of Korean descent. CO:COLLECTION_SUMMARY Samples from both cohorts were grouped together and patients with ovarian cancer CO:COLLECTION_SUMMARY (OC) and all other gynecological malignancies (non-OC) were age matched. The CO:COLLECTION_SUMMARY matched cohort included 208 patients with ovarian cancer (mean age 51.9 years) CO:COLLECTION_SUMMARY and 137 non-OC patients (mean age 49.9 years). Disease stages and histological CO:COLLECTION_SUMMARY characteristics are given in Table 1. Among the OC patients, 93 patients had CO:COLLECTION_SUMMARY early stage (I and II) cancer. Ten of the OC patients had recurrent cancer and 9 CO:COLLECTION_SUMMARY patients have had their samples collected more than once. In addition to CO:COLLECTION_SUMMARY diseased patients, samples from normal controls (women with no known CO:COLLECTION_SUMMARY gynecological malignancies) were collected during regular health exams at CO:COLLECTION_SUMMARY Severance hospital. In this case, blood was collected at least 8 hours after CO:COLLECTION_SUMMARY fasting. CO:SAMPLE_TYPE Blood (serum) #TREATMENT TR:TREATMENT_SUMMARY Serum samples were collected from two independent tissue banks in South Korea, TR:TREATMENT_SUMMARY Dongsan Hospital Human Tissue Bank and Gangnam Severance Hospital Gene Bank. The TR:TREATMENT_SUMMARY Severance cohort included 185 samples from ovarian cancer patients, 47 from TR:TREATMENT_SUMMARY women with benign ovarian tumor, 50 from invasive cervical cancer and 21 samples TR:TREATMENT_SUMMARY from patients with benign uterine tumor. Blood was collected from all patients TR:TREATMENT_SUMMARY during surgery after anesthesia and at least 8 hours of fasting. In the Dongsan TR:TREATMENT_SUMMARY cohort 88 women had ovarian cancer, 12 had benign ovarian tumor, 10 had benign TR:TREATMENT_SUMMARY uterine tumor, and 9 women had cervical cancer. As with the Severance cohort, TR:TREATMENT_SUMMARY samples from these patients were collected during surgery after anesthesia and TR:TREATMENT_SUMMARY at least 6 hours of fasting. All recruited participants were of Korean descent. TR:TREATMENT_SUMMARY Samples from both cohorts were grouped together and patients with ovarian cancer TR:TREATMENT_SUMMARY (OC) and all other gynecological malignancies (non-OC) were age matched. The TR:TREATMENT_SUMMARY matched cohort included 208 patients with ovarian cancer (mean age 51.9 years) TR:TREATMENT_SUMMARY and 137 non-OC patients (mean age 49.9 years). Among the OC patients, 93 TR:TREATMENT_SUMMARY patients had early stage (I and II) cancer. Ten of the OC patients had recurrent TR:TREATMENT_SUMMARY cancer and 9 patients have had their samples collected more than once. In TR:TREATMENT_SUMMARY addition to diseased patients, samples from normal controls (women with no known TR:TREATMENT_SUMMARY gynecological malignancies) were collected during regular health exams at TR:TREATMENT_SUMMARY Severance hospital. In this case, blood was collected at least 8 hours after TR:TREATMENT_SUMMARY fasting. As noted earlier, blood from diseased patients was collected after the TR:TREATMENT_SUMMARY initiation of anesthesia, and thus could not be directly compared with normal TR:TREATMENT_SUMMARY controls without introducing major confounding effects. Therefore, control TR:TREATMENT_SUMMARY samples were excluded from our main analysis. However, for information purposes TR:TREATMENT_SUMMARY only, we also provide a lipidome comparison between healthy controls and OC TR:TREATMENT_SUMMARY patients in supplemental information. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Serum samples were thawed on ice, followed by metabolite extraction of the SP:SAMPLEPREP_SUMMARY non-polar (lipids) metabolome. Extraction solvent was prepared by adding 725 μL SP:SAMPLEPREP_SUMMARY of the isotopically labeled lipid standard mixture to 43.5 mL 2-propanol (1:60 SP:SAMPLEPREP_SUMMARY ratio) and was kept on ice. This cold extraction solvent was added to serum SP:SAMPLEPREP_SUMMARY samples in a 3:1 ratio (solvent: serum) for protein precipitation followed by SP:SAMPLEPREP_SUMMARY vortex mixing for 15 seconds. Samples were centrifuged at 13,000 rpm for 7 SP:SAMPLEPREP_SUMMARY minutes and the resulting supernatant was transferred to LC vials. The SP:SAMPLEPREP_SUMMARY supernatant was stored at -80 °C until UHPLC-MS analysis, which was performed SP:SAMPLEPREP_SUMMARY within one week of preparation. A blank sample, prepared with LC-MS grade water, SP:SAMPLEPREP_SUMMARY underwent the same sample preparation process as the serum samples and was SP:SAMPLEPREP_SUMMARY analyzed with the rest of the samples. Pooled quality control (QC) samples were SP:SAMPLEPREP_SUMMARY prepared by combining 5-10 μL aliquots of the supernatant of each serum sample. SP:SAMPLEPREP_SUMMARY This pooled QC sample was analyzed after every 10 LC-MS runs to monitor SP:SAMPLEPREP_SUMMARY instrument stability through the course of the experiment. Samples were SP:SAMPLEPREP_SUMMARY randomized for sample preparation and were run in a randomized order on SP:SAMPLEPREP_SUMMARY consecutive days. #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Thermo Vanquish CH:COLUMN_NAME Thermo Accucore C30 (150 x 2.1mm,2.6um) CH:SOLVENT_A 10 mM ammonium acetate with water/acetonitrile (40:60 v/v) CH:SOLVENT_B 10 mM ammonium acetate with 2-isopropanol/acetonitrile (90:10 v/v). 0.1% formic CH:SOLVENT_B acid CH:FLOW_GRADIENT 0-1 min 80-40% A; 1-5 min 40-30% A; 5-5.5 min 30-15% A; 5.5-8 min 15-10% A; CH:FLOW_GRADIENT 8-8.2 min 10-0% A; 8.2-10.5 0% A; 10.5-10.7 min 0-80% A; 10.7-12.0 min 80% A. CH:FLOW_RATE 0.4 ml min-1 CH:COLUMN_TEMPERATURE 50 #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME Thermo Orbitrap ID-X tribrid MS:INSTRUMENT_TYPE Orbitrap MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_COMMENTS MS data were acquired in the 150-2000 m/z range with a 120,000 mass resolution MS:MS_COMMENTS setting. For MS/MS experiments, the Thermo Scientific Deep AcquireX data MS:MS_COMMENTS acquisition workflow was performed. Stepped normalized collision energy (NCE) of MS:MS_COMMENTS 15,30,45 was used for fragmenting precursor ions in the HCD cell followed by MS:MS_COMMENTS Orbitrap analysis at 30,000 mass resolving power. Precursor ions were also MS:MS_COMMENTS fragmented with CID energy of 40 and were analyzed in the ion trap. Data were MS:MS_COMMENTS processed in Compound Discoverer 3.3. MS:MS_RESULTS_FILE ST002521_AN004153_Results.txt UNITS:chromatographic peak area Has m/z:Neutral masses Has RT:Yes RT units:Minutes #END